NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
PR Newswire•13/10/2026•08:30 ET
0
Key Highlights
- ➤Nasdaq hearing set for November 10, 2026; NRSN shares and warrants keep trading pending decision
- ➤NeuroSense regained Nasdaq’s $1.00 minimum bid-price compliance
- ➤$35 million market-value listing deficiency remains; company may seek 180-day exception
- ➤PrimeC Health Canada New Drug Submission targeted for December 2026
- ➤PARAGON Phase 3 non-dilutive grant decision expected in Q1 2027
Expert Statements
Alon Ben-Noon, Chief Executive Officer of NeuroSense
“With bid-price compliance regained, we look forward to presenting the Panel with our plan to achieve full compliance, while advancing PrimeC toward several important near-term milestones”
Alon Ben-Noon, Chief Executive Officer of NeuroSense
“PrimeC's Phase 2b results, published in JAMA Neurology, and FDA clearance to initiate PARAGON provide a strong foundation for the next stage of development.”
Alon Ben-Noon, Chief Executive Officer of NeuroSense
“Over the coming months, we expect to file our New Drug Submission with Health Canada and receive a decision on non-dilutive grant funding that, if awarded, could support Phase 3 development while reducing our reliance on equity financing.”
Alon Ben-Noon, Chief Executive Officer of NeuroSense
“We are also pursuing strategic business development opportunities.”
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones PR Newswire
Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained
Get started
Create a free account to read the full story.